Early effects of triamcinolone on vascular endothelial growth factor and endostatin in human choroidal neovascularization

Archives of Ophthalmology

Volumn 126, Issue 2, 2008, Pages 193-199

  Tatar, Olcay ^a   Shinoda, Kei ^e   Kaiserling, Edwin ^b   Pertile, Grazia ^f   Eckardt, Claus ^c   Mohr, Andreas ^d   Yoeruek, Efdal ^a   Szurman, Peter ^a   Bartz Schmidt, Karl U ^a   Grisanti, Salvatore ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Augenklinik der Staedtischen Kliniken   (Germany)

^d Augenklinik St Joseph Stift   (Germany)

^e National Hospital Organization   (Japan)

^f SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIBODY; CYTOKERATIN 18; ENDOSTATIN; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; VERTEPORFIN;

ADULT; AGED; ANGIOGENESIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RETINA SURGERY; REVIEW; STROMA CELL; SUBRETINAL NEOVASCULARIZATION;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIGENS, CD34; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; ENDOSTATINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KERATIN-18; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETROSPECTIVE STUDIES; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 39049150409     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archophthalmol.2007.40     Document Type: Review

References (77)

1. Buch H, Vinding T, La Cour M, Appleyard M, Jensen GB, Nielsen NV. Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults: the Copenhagen City Eye Study. Ophthalmology. 2004;111(1):53-61.
2. Congdon N, O'Colmain B, Klaver CC, et al; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485.
3. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol. 2000;45(3):195-214.
4. Bressler NM; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: twoyear results of 2 randomized clinical trials: TAP report 2. Arch Ophthalmol. 2001;119(2):198-207.
5. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol. 2001;131(5):541-560.
6. Blinder KJ, Bradley S, Bressler NM, et al; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy Study Group, Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report No. 1. Am J Ophthalmol. 2003;136(3):407-418.
7. Hawkins BS; Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report No. 11. Ophthalmology. 2004;111(11):1967-1980.
8. Mruthyunjaya P, Stinnett SS, Toth CA. Change in visual function after macular translocation with 360° retinectomy for neovascular age-related macular degeneration. Ophthalmology. 2004;111(9):1715-1724.
9. Aisenbrey S, Lafaut BA, Szurman P, et al. Macular translocation with 360° retinotomy for exudative age-related macular degeneration. Arch Ophthalmol. 2002;120(4):451-459.
10. Pertile G, Claes C. Macular translocation with 360° retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol. 2002;134(4):560-565.
11. Park CH, Toth CA. Macular translocation surgery with 360° peripheral retinectomy following ocular photodynamic therapy of choroidal neovascularization. Am J Ophthalmol. 2003;136(5):830-835.
12. Fujii GY, de Juan E Jr, Humayun MS, Chang TS. Limited macular translocation for the management of subfoveal choroidal neovascularization after photodynamic therapy. Am J Ophthalmol. 2003;135(1):109-112.
13. Glacet-Bernard A, Coscas G, Soubrane G. Pigment epithelial changes in young women treated with photodynamic therapy and limited macular translocation for classic choroidal neovascularisation. Graefes Arch Clin Exp Ophthalmol. 2006;244(10):1373-1376.
14. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol. 1985;103(5):708-711.
15. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol. 2001;119(3):399-404.
16. Ciulla TA, Criswell MH, Danis RP, Hill TE. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br J Ophthalmol. 2003;87(8):1032-1037.
17. Jonas JB, Degenring RF, Kreissig I, Friedemann T, Akkoyun I. Exudative agerelated macular degeneration treated by intravitreal triamcinolone acetonide: a prospective comparative nonrandomized study. Eye. 2005;19(2):163-170.
18. Penfold PL, Gyory J, Hunyor A, Billson FA. Exudative macular degeneration and triamcinolone: a pilot study. Aust N Z J Ophthalmol. 1995;23(4):293-298.
19. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003;121(5):667-673.
20. Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina. 2006;26(6):602-612.
21. Ergun E, Maár N, Ansari-Shahrezaei S, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol. 2006;142(1):10-16.
22. Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology. 2006;113(12):2243-2250.
23. Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br J Ophthalmol. 2006;90(3):337-341.
24. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112(2):301-304.
25. Hui YN, Liang HC, Cai YS, Kirchhof B, Heimann K. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages. Graefes Arch Clin Exp Ophthalmol. 1993;231(2):109-114.
26. Chandler DB, Rozakis G, de Juan E Jr, Machemer R. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol. 1985;99(6):686-690.
27. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol. 1980;90(6):810-816.
28. Antoszyk AN, Gottlieb JL, Machemer R, Hatchell DL. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1993;231(1):34-40.
29. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology. 1996;103(12):2099-2104.
30. Leys AM, Silva R, Inhoffen W, Tatar O. Neovascular growth following photodynamic therapy for choroidal hemangioma and neovascular regression after intravitreous injection of triamcinolone. Retina. 2006;26(6):693-697.
31. Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, Provis JM. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol. 2000;121(3):458-465.
32. Penfold PL, Wen L, Madigan MC, King NJ, Provis JM. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci. 2002;43(9):3125-3130.
33. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative agerelated macular degeneration. Clin Exp Ophthalmol. 2001;29(3):188-192.
34. Kwak N, Okamoto N, Wood J, Campochiaro P. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41(10):3158-3164.
35. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-285.
36. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res. 2002;64(1):162-169.
37. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;21(8):119-126.
38. Martidis A, Miller DG, Ciulla TA, Danis RP, Moorthy RS. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther. 1999;15(5):425-428.
39. World Medical Association. Declaration of Helsinki. http://www.wma.net/e/ policy/b3.htm. Accessed November 19, 2007.
40. Tatar O, Kaiserling E, Adam A, et al. Consequences of verteporfin photodynamic therapy on choroidal neovascular membranes. Arch Ophthalmol. 2006;124(6):815-823.
41. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86(3):353-364.
42. Cui JZ, Kimura H, Spee C, Thumann G, Hinton DR, Ryan SJ. Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate. Graefes Arch Clin Exp Ophthalmol. 2000;238(4):326-333.
43. Baffi J, Byrnes G, Chan CC, Csaky KG. Choroidal neovascularization in the rat induced by adenovirus mediated expression of vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 2000;41(11):3582-3589.
44. Tatar O, Shinoda K, Adam A, et al. Effect of verteporfin photodynamic therapy on endostatin expression and angiogenesis in human choroidal neovascular membranes. Br J Ophthalmol. 2007;91(2):166-173.
45. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37(9):1929-1934.
46. Amin R, Pulkin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci. 1994;35(8):3178-3188.
47. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37(5):855-868.
48. Tatar O, Shinoda K, Adam A, et al. Expression of endostatin in human choroidal neovascular membranes secondary to age-related macular degeneration. Exp Eye Res. 2006;83(2):329-338.
49. Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006;142(1):95-104.
50. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular agerelated macular degeneration. N Engl J Med. 2004;351(27):2805-2816.
51. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(4):632.e1. http://www.ophsource.org/periodicals/ophtha/article/PIIS0161642006001060/ abstract. Accessed November 21, 2007.
52. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113(4):642.e1-642.e4. http://www.ophsource.org/periodicals/ophtha/article/PIIS0161642005014247/ abstract. Accessed November 21, 2007.
53. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363-372.
54. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol. 2004;122(12):1801-1807.
55. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341(2-3):309-315.
56. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci. 2005;46(3):1062-1068.
57. Tong JP, Lam DS, Chan WM, Choy KW, Chan KP, Pang CP. Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umbilical vein endothelial cells. Mol Vis. 2006;12:1490-1495.
58. Obata R, Iriyama A, Inoue Y, Takahashi H, Tamaki Y, Yanagi Y. Triamcinolone acetonide suppresses early proangiogenic response in RPE cells after photodynamic therapy in vitro. Br J Ophthalmol. 2007;91(1):100-104.
59. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40(9):1891-1898.
60. Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(8):3578-3585.
61. Hasan Q, Tan ST, Xu B, Davis PF. Effects of five commonly used glucocorticoids on haemangioma in vitro. Clin Exp Pharmacol Physiol. 2003;30(3):140-144.
62. Gao H, Qiao X, Gao R, Mieler WF, McPherson AR, Holz ER. Intravitreal triamcinolone does not alter basal vascular endothelial growth factor mRNA expression in rat retina. Vision Res. 2004;44(4):349-356.
63. Hasan Q, Tan ST, Gush J, Peters SG, Davis PF. Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics. 2000;105(1, pt 1):117-120.
64. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113(12):1538-1544.
65. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003;44(5):2147-2154.
66. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroids. Invest Ophthalmol Vis Sci. 2002;43(3):830-841.
67. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996;98(7):1667-1675.
68. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization [published correction appears in Am J Pathol. 2000;157(4):1413]. Am J Pathol. 2000;157(1):135-144.
69. Mori K, Ando A, Gehlbach P, et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol. 2001;159(1):313-320.
70. Takahashi K, Saishin Y, Saishin Y, et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J. 2003;17(8):896-898.
71. Folkman J. Endogenous angiogenesis inhibitors. APMIS. 2004;112(7-8):496-507.
72. Wu P, Yonekura H, Li H, et al. Hypoxia down-regulates endostatin production by human microvascular endothelial cells and pericytes. Biochem Biophys Res Commun. 2001;288(5):1149-1154.
73. Nasu K, Nishida M, Fukuda J, Kawano Y, Nishida Y, Miyakawa I. Hypoxia simultaneously inhibits endostatin production and stimulates vascular endothelial growth factor production by cultured human endometrial stromal cells. Fertil Steril. 2004;82(3):756-759.
74. Bhutto IA, Kim SY, McLeod DS, et al. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with agerelated macular degeneration. Invest Ophthalmol Vis Sci. 2004;45(5):1544-1552.
75. Abdollahi A, Lipson KE, Sckell A, et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 2003;63(24):8890-8898.
76. Pan X, Wang Y, Zhang M, Pan W, Qi ZT, Cao GW. Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis. World J Gastroenterol. 2004;10(10):1409-1414.
77. Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol. 2006;142(6):1072-1074.